Skip to Content
Reach blood sugar goals with long-acting insulin. Go >

Acarbose Disease Interactions

There are 5 disease interactions with acarbose:

Major

Acarbose (Includes Acarbose) ↔ Cirrhosis

Severe Potential Hazard, Moderate plausibility

Applies to: Cirrhosis

The use of acarbose is contraindicated in patients with primary cirrhosis.

Major

Acarbose (Includes Acarbose) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Acarbose may accumulate in patients with renal impairment. Following oral administration, 35% of a dose is recovered in the urine as either the parent drug or metabolites. However, long-term clinical trials in diabetic patients with significant renal dysfunction (serum creatinine > 2.0 mg/dL) have not been conducted. Therapy with acarbose should be administered cautiously in patients with renal dysfunction. The manufacturer does not recommend its use in patients with significantly impaired renal function.

References

  1. "Product Information. Precose (acarbose)." Bayer, West Haven, CT.
  2. Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
  3. Balfour JA, McTavish D "Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus [published erratum appears in Drugs 1994 Dec;48(6):929]." Drugs 46 (1993): 1025-54
Major

Alpha-Glucosidase Inhibitors (Includes Acarbose) ↔ Diabetic Ketoacidosis

Severe Potential Hazard, Moderate plausibility

Applies to: Diabetic Ketoacidosis

The use of alpha-glucosidase inhibitors is contraindicated for the treatment of patients with diabetic ketoacidosis.

Major

Alpha-Glucosidase Inhibitors (Includes Acarbose) ↔ Intestinal Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Colonic Ulceration, Intestinal Obstruction, Malabsorption Syndrome, Colitis/Enteritis (Noninfectious)

The use of alpha-glucosidase inhibitors is contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease associated with marked disorders of digestion or absorption. Alpha-glucosidase inhibitors competitively inhibit enzymes involved in the digestion of carbohydrates. Increased gas formation in the intestines due to fermentation of the undigested carbohydrates can worsen or aggravate intestinal problems.

References

  1. Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992): 47-53
  2. Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
  3. "Product Information. Glyset (miglitol)." Bayer, West Haven, CT.
View all 5 references
Moderate

Acarbose (Includes Acarbose) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of acarbose has been associated with dose-related elevations in serum transaminase levels and, rarely, hyperbilirubinemia and jaundice. Hepatic adverse effects may be more likely to occur at dosages exceeding 50 mg three times a day. Therapy with acarbose should be administered cautiously in patients with liver disease. The manufacturer states that its use is contraindicated in patients with cirrhosis. Monitoring of serum transaminases is recommended every 3 months during the first year of treatment and periodically thereafter. If hepatotoxicity is suspected at any time, a dosage reduction or withdrawal of therapy may be indicated.

References

  1. Hollander P "Safety profile of acarbose, an alpha-glucosidase inhibitor." Drugs 44 Suppl 3 (1992): 47-53
  2. Clissold SP, Edwards C "Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential." Drugs 35 (1988): 214-43
  3. "Product Information. Precose (acarbose)." Bayer, West Haven, CT.
View all 5 references

acarbose drug Interactions

There are 649 drug interactions with acarbose

acarbose alcohol/food Interactions

There is 1 alcohol/food interaction with acarbose

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide